DÄ internationalArchive41/2007Human Papillomavirus and Cervical Cancer

Review article

Human Papillomavirus and Cervical Cancer

Dtsch Arztebl 2007; 104(41): A-2806

Löning, M; Gissmann, L; Diedrich, K; Friese, K; Kreienberg, R; Hillemanns, P

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Griffiths M: Nuns, virgins, and spinsters. Rigoni-Stern and cervical cancer revisited. Br J Obst Gynaecol 1991; 98: 797–802. MEDLINE
2. Gissmann L: Linking Human Papillomaviruses to Cervical Cancer: A Long and Winding Road. In: Campo MS (Hrsg.): Papillomavirus Research: From Natural History To Vaccines and Beyond. Norwick UK: Caister Academic Press 2006; 3–11.
3. Munoz N, Bosch FX: HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ 1992; 119: 251–61. MEDLINE
4. Koutsky LA, Ault KA, Wheeler CM et al.: Proof of principle study investigators. a controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51. MEDLINE
5. Harper DM, Franco EL, Wheeler C et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757–65. MEDLINE
6. Villa LL, Costa RL, Petta CA et al.: Prophylactic tetravalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–8. MEDLINE
7. The FUTURE II Study Group: Tetravalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915–27. MEDLINE
8. Ault KA, The Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007; 369: 1861–8. MEDLINE
9. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–43. MEDLINE
10. Joura EA, Leodolter S, Hernandez-Avila M et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007; 369: 1693–702. MEDLINE
11. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367: 1247–55. MEDLINE
12. Villa LL, Costa RL, Petta CA et al.: High sustained efficacy of a prophylactic tetravalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 2006; 95: 1459–66. MEDLINE
13. Block SL, Nolan T, Sattler C et al.: Comparison of the immunogenicity and reactogenicity of a prophylactic tetravalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135–45. MEDLINE
14. Paavonen J, Jenkins D, Bosch FX et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007; 369: 2161–70. MEDLINE

Info

Specialities